Mineralys Therapeutics, Inc.
MLYS
$39.20
$0.050.13%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.68M | 8.47M | 6.57M | 7.20M | 6.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.13M | 46.75M | 44.45M | 51.77M | 60.11M |
| Operating Income | -41.13M | -46.75M | -44.45M | -51.77M | -60.11M |
| Income Before Tax | -36.93M | -43.27M | -42.21M | -48.95M | -56.34M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.93M | -43.27M | -42.21M | -48.95M | -56.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.93M | -43.27M | -42.21M | -48.95M | -56.34M |
| EBIT | -41.13M | -46.75M | -44.45M | -51.77M | -60.11M |
| EBITDA | -41.12M | -46.73M | -44.43M | -51.75M | -60.10M |
| EPS Basic | -0.52 | -0.66 | -0.79 | -0.98 | -1.13 |
| Normalized Basic EPS | -0.33 | -0.41 | -0.50 | -0.61 | -0.71 |
| EPS Diluted | -0.52 | -0.66 | -0.79 | -0.98 | -1.13 |
| Normalized Diluted EPS | -0.33 | -0.41 | -0.50 | -0.61 | -0.71 |
| Average Basic Shares Outstanding | 70.59M | 65.45M | 53.16M | 49.96M | 49.82M |
| Average Diluted Shares Outstanding | 70.59M | 65.45M | 53.16M | 49.96M | 49.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |